# Geisinger

## Introduction

- Hemolytic uremic syndrome (HUS) is clinically diagnosed from the triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal injury.
- So-called "typical" HUS (Shiga toxin or ST-HUS) is most often caused by Shiga toxin-producing E. coli O157:H7 infection<sup>1</sup>.
- HUS as a complication of *Clostridioides difficile* infection (CDI) is rare, with only 11 cases reported in adults.
- We present a case of a patient presenting with the classic triad of HUS, which was found to be due to non-complement mediated typical HUS from CDI.

| Case              | Age | Sex      | Diarrhea | Confusion | Dialvsis | Plasmapharesis | Pharmaceu    |
|-------------------|-----|----------|----------|-----------|----------|----------------|--------------|
|                   |     |          | Non      |           |          |                |              |
| Mogyorosi 1997    | 5   | 1Female  | bloody   | Yes       | No       | No             | Oral and red |
| Mbonu, 2003       | 40  | 6Female  | Bloody   | No        | Yes      | Yes            | Oral metror  |
|                   |     |          | non      |           |          |                |              |
| Kalmanovich 2012  | 73  | 3 Female | bloody   | no        | Yes      | No             | IV metronid  |
| Keshtkar-Jahromi, |     |          | Non      |           |          |                |              |
| 2012              | 62  | 2 Female | bloody   | Yes       | Yes      | yes            | Intravenous  |
|                   |     |          | non      |           |          |                |              |
| Alvarado 2014     | 29  | 9Female  | bloody   | no        | No       | No             | Oral vancon  |
|                   |     |          | non      |           |          |                |              |
| Alvarado 2014     | 52  | 2 Female | bloody   | yes       | No       | yes            | Oral metror  |
|                   |     |          |          |           |          |                | IV metronid  |
| Alvarado 2014     | 63  | 3 Female | bloody   | yes       | No       | yes            | eculizumab   |
|                   |     |          | non      |           |          |                | Plasmaphar   |
| IInglis 2018      | 4   | 6Male    | bloody   | no        | Yes      | yes            | metronidaz   |
|                   |     |          | Non      |           |          |                | IV metronid  |
| Khurshid 2020     | 6   | OFemale  | bloody   | No        | Yes      | yes            | eculizumab   |
|                   |     |          | Non      |           |          |                |              |
| Wadehra 2021      | 6   | 5 Male   | bloody   | No        | Yes      | No             | Oral vancon  |
|                   |     |          |          |           |          |                | IV metronid  |
| Moulton 2021      | 2   | 1Female  | Bloody   | Yes       | Yes      | No             | eculizumab   |
|                   |     |          |          |           |          |                |              |

Table 1. A review of the medical literature revealed 11 previously reported cases of hemolytic uremic syndrome caused by CDI.

## Biopsy-proven typical hemolytic uremic syndrome (HUS) as a rare complication of Clostridioides difficile infection

Vandan Shah, MD<sup>1</sup>; Samarth Patel, MD<sup>1</sup>; David L Diehl, MD<sup>1,2</sup> <sup>1</sup>Geisinger Medical Center, <sup>2</sup>Department of Gastroenterology

## **Case Presentation**

- A 43-year-old female with a past medical history of non-alcoholic steatohepatitis (NASH) cirrhosis was found unconscious with a 3-day history of loose bloody bowel movements, diaphoresis, and chills.
- Initial blood pressure was 186/97 mmHg and pulse of 110. Lactate dehydrogenase was 1223 U/L, peripheral blood smear.
- ADAMTS13 protease level came back normal at 0.95 IU/mL and inhibitor level undetectable at <0.4 BEU, negative for Shiga toxin but positive for *C.diff*. The patient was started on oral vancomycin.
- After complement-mediated HUS serum and plasma panel labs and genetic susceptibility panel labs returned negative for complement-mediated HUS, the leading diagnosis was so-called "typical" HUS.
- vancomycin treatment, the patient's symptoms completely resolved.

#### tical Intervention

- ctal vancomycin
- nidazole
- lazole and steroids
- metronidazole and steroids
- nycin and steroids
- idazole dazole, Oral vancomycin,
- resis, Oral vancomycin, IV zole, eculuzimab dazole, Oral vancomycin,
- nycin, steroids dazole, oral vancomycin and surgery



Figure 1. Kidney biopsy showed: (A) fibrin thrombi and neutrophils within the capillary loops of the glomeruli. RBC fragmentation is evident within capillary loops and the mesangium. (B) Mesangiolysis and endothelial cell swelling.

creatinine 6.5 mg/dL, haptoglobin <10 mg/dL, platelets 98 K/uL, and there were schistocytes on

suggesting the diagnosis of HUS. The patient's complement levels were normal (C3=119 mg/dL, C4=26 mg/dL). Renal biopsy showed thrombotic microangiopathy without fibrosis. Stool pathogen panel was

• Thrombocytopenia and anemia improved dramatically after only a few sessions of plasmapheresis. After



## Discussion

- Our patient presented with the classic triad of thrombocytopenia, hemolytic anemia and renal failure with a renal biopsy showing thrombotic microangiopathy, confirming the diagnosis of HUS.
- A unique aspect of the case was typical HUS in an adult that was caused by an organism not commonly associated with HUS.
- It is unknown how CDI can trigger HUS in the absence of Shiga toxin. One theory is that like Shiga toxin, the toxins A and B of *C.diff* can induce apoptosis of the colonic cell membrane and release cytokines into circulation inducing a proinflammatory and hypercoagulable state <sup>1,3,4</sup>.

## Conclusion

- Our case was the only one to confirm the diagnosis of HUS by renal biopsy with further classification of "typical" HUS with negative advanced complement and genetic studies
- C.diff is a rare cause of HUS. Proper treatment to complete resolution without lead can recurrence.

### References

| 1. | Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Neph. 2005;16:1035–     |
|----|---|
|    | 50.   |
| 2. | Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic |
|    | syndrome: Causes and short-term course. Am J of Kidney Dis. 2004:43:976–82.     |

- Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: Review. Eur J of Clin Microbiol & Inf Dis. 2019;38:1211-21.
- Mbonu CC, Davison DL, El-Jazzar KM, et al. Clostridium difficile colitis associated with hemolytic-uremic syndrome. Am J Kidney Dis. 2003;41(5) e14-1.